Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
UK consumer confidence plunges amid escalating Iran conflict - 2Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- 3Best bar-b-que Style: Which One Is Your Number one?
- 4Vote in favor of the handheld vacuum that you love for its strong attractions!
- 56 Home Cleaning Administrations to Keep Your Home Unblemished
- Avoid Slam: Exploring the Pickup Truck Transformation
- This is Countdown, CNN’s newsletter covering NASA’s first time sending humans to deep space in over 50 years
- The Magnificence of Do-It-Yourself Skincare: Regular Recipes and Tips
- We analyzed Philly street scenes and identified signs of gentrification using machine learning trained on longtime residents’ observations
- Images of Bangladeshi motorcyclists sleeping at petrol pumps are AI-generated
- Find the Historical backdrop of Common liberties: Advancing Equity and Equity Around the world
- The most effective method to Decide the Best Auto Crash Attorney for Your Lawful Necessities
- Tens of thousands protest as far-right AfD forms new youth group
- Remarkable Spots for Hot Air Swelling All over The Planet
